Treating Shiga toxin induced haemolytic uraemic syndrome

BMJ (Online)

Volumn 345, Issue 7869, 2012, Pages

  Artunc, Ferruh ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; COMPLEMENT COMPONENT C3; ECULIZUMAB; GLUCOCORTICOID; MEROPENEM; RIFAXIMIN; SHIGA TOXIN; ANTIINFECTIVE AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ARTIFICIAL VENTILATION; BACTERIAL VIRULENCE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE SEVERITY; EDITORIAL; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ETHNIC GROUP; FECES ANALYSIS; FENUGREEK; FOOD CONTAMINATION; GERMAN; HEMOLYTIC UREMIC SYNDROME; HUMAN; INDIVIDUALIZATION; INTENSIVE CARE; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; PATHOGENESIS; PATIENT CARE; PLASMAPHERESIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TREATMENT OUTCOME; ANIMAL; EPIDEMIC; ESCHERICHIA COLI INFECTION; FEMALE; MALE; NOTE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE OUTBREAKS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; MALE;

EID: 84864875001     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4598     Document Type: Editorial

References (12)

1. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005;16:1035-50. (Pubitemid 41710314)
2. Michael M, Elliott EJ, Craig JC, Ridley G, Hodson EM. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009;53:259-72.
3. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012;345:e4565.
4. Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011;365:1763-70.
5. Bielaszewska M, Mellmann A, Zhang W, Köck R, Fruth A, Bauwens A, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011;11:671-6.
6. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, et al. N Engl J Med 2011;364:2561-3.
7. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-6. (Pubitemid 30419087)
8. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, et al. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012;56:3277-82.
9. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011;378:1089-93.
10. Artunc F, Amann K, Haap M. [Hemolytic uremic syndrome following EHEC infection.] Dtsch Med Wochenschr 2011;136:1917.
11. Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009;182:6394-400.
12. Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011;187:172-80.